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A 1-year prospective case-control study (ratio of control patients to case patients, 3:1) was performed to assess
the incidence, risk factors, and genotypic patterns of bacteremia caused by glycopeptide-resistant coagulase-
negative staphylococci (CoNS) and their correlation with hospital glycopeptide use. Among 535 subjects with
CoNS bacteremia, 20 subjects had a glycopeptide-resistant strain (19 strains were resistant to teicoplanin and
1 was resistant to both teicoplanin and vancomycin). The percentage of resistant isolates recovered in 1 year
was 8% in intensive care units and 3% and 2% in medical and surgical wards, respectively. Genotypic analysis
of resistant strains showed different patterns with a high degree of polymorphism. Use of glycopeptides in
individual wards was not statistically associated with the percentage of resistance. Previous exposure to b-
lactams and glycopeptides, multiple hospitalization in the previous year, and concomitant pneumonia were
significantly associated with the onset of glycopeptide-resistant CoNS bacteremia. Mortality rates were 25%
among case patients and 18% among control patients, and they were significantly higher among patients who
presented with concomitant pneumonia and a high Acute Physiology and Chronic Health Evaluation III score.
At present, glycopeptides are among the last available
antibiotics, with quinupristin-dalfopristin and linezolid
[1, 2], for treating multidrug-resistant, gram-positive
nosocomial infections, which are mostly caused by
methicillin-resistant staphylococci and enterococci
[3–6]. The first 2 cases of infection with glycopeptide-
resistant Staphylococcus haemolyticus were reported in
1986 [7, 8], and, recently, a worldwide increase in the
number of observations of glycopeptide-resistant co-
agulase-negative staphylococci (CoNS) has been de-
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scribed elsewhere [9–13]. Furthermore, Hiramatsu et
al. [14] were the first researchers to report a case of
infection caused by S. aureus with reduced susceptibility
to vancomycin in May 1996. Of interest, vancomycin
had been in clinical use for almost 30 years before high-
level resistant strains emerged. Such strains can natu-
rally occur or they can develop through low-level mu-
tational resistance. In fact, the genes responsible for
vancomycin resistance in enterococci can transfer to
more-virulent organisms, such as staphylococci [4]. To
underline this growing alarm, the Centers for Disease
Control and Prevention (CDC) in Atlanta provided rec-
ommendations in 1997 for prudent vancomycin use,
to prevent the spread of vancomycin-resistant staphy-
lococci [15].
Despite several reports that described microbiolog-
ical characteristics of glycopeptide-resistant CoNS, to
our knowledge, the clinical and epidemiological find-
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ings of these infections have not been extensively described in
vivo. Only a single retrospective report from Hong Kong in-
dicated that patients with vancomycin-resistant CoNS bacte-
remia were preferentially admitted to intensive care units
(ICUs) and had previously received vancomycin more often
than did control patients [9].
The purposes of this study were to define, through a 1-year
surveillance, the incidence and the risk factors of glycopeptide
resistance among strains of CoNS that caused bacteremia. We
also analyzed the genotypic patterns of glycopeptide-resistant
CoNS and the correlation between glycopeptide use in indi-
vidual wards and the development of glycopeptide resistance.
PATIENTS AND METHODS
Study setting. The Catholic University hospital (Rome) is a
1700-bed tertiary care center with ∼60,000 patient admissions
each year that come mostly from central and southern Italy
and, to a lesser extent, from northern Italy. The hospital has
medical, surgical, and neonatal specialties, as well as intensive
care and postsurgical units. Kidney, liver, and bone marrow
transplantation are performed. There is a 60-bed unit for the
admission of HIV-infected patients and a day hospital for their
outpatient care.
Study design. From 1 July 1998 through 30 June 1999, all
blood cultures processed by the clinical microbiology laboratory
and yielded staphylococci were identified through a daily review
of the laboratory computer summary report. All subjects aged
118 years with CoNS bacteremia were included in the study.
The definition of CoNS bacteremia was based on that of the
CDC and required 2 blood isolations of CoNS obtained in
presence of fever (body temperature, 38C) that was not at-
tributable to other causes [16]. In particular, all patients who
had CoNS bacteremia caused by glycopeptide-resistant strains
were designated “case patients.” For each case patient, we ran-
domized (using the table of random numbers) 3 control pa-
tients among subjects with CoNS bacteremia caused by gly-
copeptide-susceptible strains and the same “geography” of
infection (nosocomially or community-acquired) of the cor-
responding case patient. Patients in whom staphylococci were
isolated within 48 h after admission were assumed to have a
community-acquired infection. The study was observational,
because the administration of antimicrobial agents and other
therapeutic management was controlled by patients’ physicians
and not by the investigators.
A standardized questionnaire was administered by the med-
ical investigator, after receiving consent from the patient, during
the patient’s hospital stay. The following data were obtained:
age; sex; presence of underlying diseases; ward; number of hos-
pital admissions in the year prior to the study; number of
polymorphonuclears/mm3; nutritional status (expressed by
body weight and albumin level); previous bacterial infections;
receipt of corticosteroid therapy; presence and type of central
venous catheter or of other catheters; history of surgery, en-
doscopy, alcoholism, cirrhosis, diabetes, neoplastic disease, and
chronic renal failure; previous receipt of antimicrobial therapy
or other medications (if the drug was taken for at least 7 of
the 30 days before the onset of infection); duration of previous
antimicrobial therapy; bacteremia therapy; results of a sensi-
tivity test to antibiotics; vital signs; outcome and/or cause of
death, as listed by the attending physicians; and total length of
hospitalization. The risk factors were recorded only if they were
present during the 30 days before the development of infection.
Prognosis immediately prior to the development of bacteremia
was assigned by use of the McCabe index [17]. The revised
Acute Physiology and Chronic Health Evaluation (APACHE)
was assigned by the APACHE III system [18].
To establish the relationship between previous hospital use
of glycopeptides and development of glycopeptide-resistant
CoNS bacteremia, we calculated the defined daily dose (DDD)
for teicoplanin and for vancomycin in individual wards during
the study period by analyzing the hospital pharmacy data.
Amounts of parenteral glycopeptides were standardized by con-
version to DDDs, for which 1 DDD was equivalent to 2 g for
vancomycin and 400 mg for teicoplanin. For each ward, mean
rates for the study were calculated by dividing the total number
of DDDs by the total number of patient-days reported during
the study period, and they were expressed as DDDs per 1000
patient-days.
Identification of organisms and susceptibility testing.
Species identification was performed using the API test
(bioMe´rieux). Isolates were frozen at 70C until needed and
were tested by means of the broth microdilution method de-
scribed by the National Committee for Clinical Laboratory
Standards (NCCLS), with cation-adjusted Mueller Hinton
broth (Difco Laboratories) [19, 20]. The antimicrobial agents
tested included ciprofloxacin, clindamycin, erythromycin, gen-
tamicin, oxacillin, penicillin, teicoplanin, trimethoprim-sulfa-
methoxazole, and vancomycin. In addition, MICs for teico-
planin and vancomycin were determined for each isolate using
the E-test (AB Biodisk), in accordance with the manufacturer’s
instructions. Susceptibility tests were performed by use of a
bacterial inoculum whose turbidity was equivalent to that of a
0.5 McFarland turbidity standard. The suspension was used to
inoculate Mueller Hinton agar plates by swabbing them with
a cotton swab. The plates were incubated for 18 h in air at
35C. The MICs were interpreted as the point of intersection
of the inhibition ellipse with the E-test strip edge. The quality-
control strains of S. aureus American Type Culture Collection
(ATCC) 29213 and S. aureus ATCC 43300 were included with
each run. The interpretation of results was performed according
to recommendations of the NCCLS [20]. In particular, teico-
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Table 1. Multiple-antibiotic resistance in 535 strains obtained from subjects with bacteremia
caused by coagulase-negative staphylococci (CoNS).
Drug or drug class
No. (%) of CoNS strains resistant to
(n p 535)
Methicillin Aminoglycosides Quinolones Macrolides TMP-SMZ
Glycopeptides (n p 20) 19 (95) 19 (95) 17 (85) 17 (85) 18 (90)
Methicillin (n p 372) 372 (100) 307 (83) 228 (61) 298 (80) 241 (65)
Aminoglycosides (n p 339) 298 (88) 339 (100) 227 (67) 291 (86) 231 (68)
Quinolones (n p 249) 228 (92) 230 (92) 249 (100) 212 (85) 181 (73)
NOTE. TMP-SMZ, trimethoprim-sulfamethoxazole.
planin resistance was defined by an MIC of 118 mg/mL, whereas
vancomycin resistance was defined by an MIC of 8 mg/mL.
Ribotyping. All glycopeptide-resistant strains were subjected
to genotypic analysis. The chromosomal DNA of the isolates was
extracted as reported elsewhere [21]. For digestion, DNA was
incubated with l HindIII restriction enzyme (Promega), ac-
cording to the recommendations of the manufacturer. Agarose
gel electrophoresis was performed using a horizontal gel appa-
ratus (model HE 99; HSI). Samples were loaded into wells in a
0.7% agarose gel (Boerhinger Mannheim) and electrophoresed
at 30 V for 14–18 h. Electrophoresis was performed at room
temperature in TAE buffer (0.04 M Tris-acetate [Boerhinger
Mannheim] and 0.001 M EDTA, pH 8.0). Gels were stained with
a solution of ethidium bromide. The 1.8 kb ApaI clone [22–24]
and l DNA were used as probes. The DNA of the isolates was
transferred to supported nitrocellulose (Nitroplus 200; MSI) by
use of a vacuum transfer device (ABN), and Southern blots were
performed by a modification of the method of Southern [25].
Hybridization was performed at 68C, and the blots were washed
at 68C with (0.15 M NaCl and 0.015 M sodium0.1 SSC
citrate, pH 7.0) and 0.1% sodium dodecyl sulfate. Probes were
labeled with enhanced chemiluminescent gene-labeling kit
(Amersham International). Autoradiography was performed at
room temperature by use of Kodak X-RP films.
Computers analysis of fingerprints. The patterns pro-
duced by the ribotyping method were evaluated using the Image
master software (Pharmacia Biotechnology). All bands pro-
duced were normalized by comparing molecular weight mark-
ers (l HindIII DNA) between different gels, and the molecular
weight of the hybridizing bands was calculated using the Image
master software.
Statistical analysis. Quantitative variables were tested for
distribution (by use of normal probability plot and Shapiro
Wilks test) and compared by use of the Kruskal-Wallis test.
Differences in group proportions were assessed with the x2 and
Fisher’s exact tests. Potential risk factors for the development
of glycopeptide resistance were analyzed by use of univariate
methods, to identify differences in patients who developed and
who did not develop glycopeptide-resistant staphylococcal bac-
teremia. The 95% test-based CIs (95% CIs) were used to de-
terminate the statistical significance of the OR. Stepwise logistic
regression models were used for each factor to adjust for the
effects of confounding variables. Two-tailed tests of significance
at the level were used to determine statistical signif-P 0.05
icance. Statistical analysis was performed by use of the software
program Intercooled Stata, version 6.0, for Windows 98 (Stata
Corporation).
RESULTS
During the study period, 46,223 adult patients were hospital-
ized, and blood samples were obtained from 10,547 for 26,226
blood cultures. Staphylococci were isolated from 1622 blood
cultures. A diagnosis of CoNS bacteremia was made for 535
subjects, with 1235 blood cultures that yielded CoNS (5%; 535/
10,547). The isolated strains of CoNS were Staphylococcus ep-
idermidis (70%), Staphylococcus hominis (12%), S. haemolyticus
(9%), Staphylococcus capitis (6%), Staphylococcus warneri (2%),
and other CoNS species (1%).
Antimicrobial resistance. Table 1 shows details of mul-
tiple-antibiotic resistance for 535 strains of CoNS. In particular,
88 (16%) of 535 strains of CoNS were susceptible to all the
following antibiotics: methicillin, aminoglycosides, quinolones,
macrolides, and trimethoprim-sulfamethoxazole. Among the
163 methicillin-susceptible strains, 44 (27%) were penicillin
susceptible.
Glycopeptide resistance. Twenty strains of CoNS were re-
sistant to glycopeptide (19 strains were resistant to teicoplanin
only and 1 strain was resistant to both teicoplanin and van-
comycin), with an overall incidence of 4%. The incidence of
resistance per ward was 8% for the ICU, 3% for the medical
wards, and 2% for the surgical wards.
Figure 1 shows the relationship between the incidence of
glycopeptide resistance per ward and the ward use of glyco-
peptides during the study period. If we consider the entire
hospital, the median DDD (SD) for glycopeptide use was
for teicoplanin and for vanco-41.67 25.66 34.37 32.71
mycin. The analyzed data did not show any significant corre-
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Figure 1. Relationship between the incidence of glycopeptide-resistant coagulase-negative staphylococci bacteremia in individual ward and the
glycopeptide ward use.
lation between ward use of glycopeptide (expressed by DDD)
and the percentage of glycopeptide-resistant strains of CoNS
isolated in the single ward.
Risk factors analysis. Twenty patients with CoNS bacte-
remia (S. epidermidis in 18 cases and S. haemolyticus in 2 cases)
met the aforementioned case definition, and they were matched
with 60 randomized control subjects, for a total of 80 subjects.
The majority of cases of bacteremia (69 [86%] of 80) were
hospital acquired. Table 2 summarizes the data regarding the
study population.
Comparison of the case patients and control patients, by
univariate analysis, indicated remarkable differences in the dis-
tribution of known and potential risk factors (see table 2).
Previous administration of b-lactams and glycopeptides, me-
chanical ventilation, use of total parenteral nutrition, multiple
hospital admissions in the year prior to the study period, con-
comitant pneumonia, number (3) of antibiotic treatments,
admission to ICU, and presence of multiple (13) risk factors
for bacteremia were significantly different in the 2 groups of
patients. Moreover, isolation of methicillin- (95% vs. 65%; OR,
10.23; 95% CI, 1.27–59.62; ), aminoglycoside- (95%Pp 0.008
vs. 57%; OR, 14.52; 95% CI, 1.83–78.04; ), and quin-Pp 0.001
olone- (85% vs. 50%; OR, 5.66; 95% IC, 1.35–27.31; Pp
) resistant strains were significantly more common among0.007
the case patients than they were among control patients, re-
spectively. Case patients did not differ significantly from con-
trols with regard to the duration of previous antibiotic therapy.
The clinically important conditions and treatments most
strongly associated with the development of glycopeptide re-
sistance ( , by univariate analysis) were further analyzedP ! 0.2
by use of logistic regression. Previous administration of b-lac-
tams and glycopeptides, multiple hospital admissions, and pres-
ence of pneumonia were found to be independent predictors
of glycopeptide resistance (see table 3). Stepwise entry of sex
and age into the model yielded similar results.
Genotype analysis. Eighteen strains of S. epidermidis with
an MIC of teicoplanin of 118 mg/ml were clustered into 15
different patterns by ribotyping that used, as a probe, an rrn
cloned fragment from Enterococcus hirae. Unfortunately, 2
strains of S. haemolyticus (1 that was resistant to teicoplanin
and 1 that was resistant to both glycopeptides) were not avail-
able for further evaluation. The patterns were clearly inter-
pretable, with a number of bands ranging from 12 to 20 hy-
bridizing bands. The results showed a high degree of
polymorphism among these isolates, which indicates that cases
of glycopeptide-resistant bacteremia were not owing to an out-
break of a single or few strains but to several different strains
of S. epidermidis with a decreased susceptibility to teicoplanin
(see table 4 and figure 2). Some of the strains generated the
same pattern A (strains 29, 93, and 95) (figure 2, lanes H, I,
and L). These strains were isolated from different wards. Strains
808 and 843, which were isolated from the ICU and medical
ward, respectively, produced the same pattern O (table 4).
Outcome. The mean duration of total hospitalization
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Table 2. Demographic data for 20 patients with bacteremia caused by glycopeptide-resistant coagulase-
negative staphylococci (CoNS; case patients) and 60 randomized patients with bacteremia caused by gly-





(n p 60) Pa OR (95% CI)
Sex, no. male/no. female 13/7 42/18 0.67 1.25 (0.44–3.59)
Age, mean years  SD 56  18 59  18 0.65 —
Hospital ward
Medicine 7 (35) 36 (60) 0.09 0.35 (0.10–1.15)
Hematology 1 (5) 5 (8) 1.00 0.57 (0.06–5.74)
Infectious diseases 1 (5) 8 (13) 0.53 0.34 (0.04–3.05)
Surgery 2 (10) 11 (18) 0.59 0.49 (0.10–2.75)
Intensive care unit 11 (55) 13 (22) 0.01 4.41 (1.33–14.93)
Mean APACHE III score  SD 34  15 33  16 0.99 —
McCabe score
Rapidly fatal 5 (25) 9 (15) 0.49 1.88 (0.46–7.54)
Ultimately fatal 8 (40) 21 (35) 0.89 1.23 (0.38–3.93)
Nonfatal 7 (35) 30 (50) 0.36 0.53 (0.16–1.71)
Nosocomial episodes 17 (85) 52 (87) 0.85 0.87 (0.17–4.70)
Duration of hospitalization, mean days  SD 83  93 54  64 0.07 —
Concomitant pneumonia 17 (85) 26 (43) 0.001 7.41 (2.07–26.03)
Central catheterization 12 (60) 28 (47) 0.30 1.71 (0.62–4.68)
Total parenteral nutrition 15 (75) 22 (37) 0.003 5.18 (1.70–15.61)
Mechanical ventilation 11 (55) 10 (17) 0.001 6.11 (2.05–18.28)
Previous bacterial infections 4 (20) 7 (12) 0.57 1.89 (0.40–8.60)
Previous antibiotic therapy
Multiple treatment 13 (65) 21 (35) 0.01 3.44 (1.21–9.72)
Glycopeptides 6 (30) 5 (8) 0.01 4.71 (1.32–16.87)
b-Lactams 17 (85) 21 (35) 0.0001 10.52 (2.91–37.31)
13 risk factors 6 (30) 5 (8) 0.04 4.71 (1.06–21.55)
Previous hospitalizations, no.
1 6 12 — 2.62 (0.73–9.34)
2 4 5 — 4.20 (0.86–20.42)
3 2 1 0.007b 10.5 (0.73–150.5)
NOTE. Data are no. (%) of patients, unless otherwise indicated. APACHE, Acute Physiology and Chronic Health Evaluation.
a Significance of finding by comparison of case patients with control patients. P values are 2-tailed and were determined by use
of Fisher’s exact test and Student’s t test, unless otherwise indicated.
b
x2 for trend.
(SD) was days for the 20 case patients and83 93 54
days for the 60 control patients ( ). All patients64 Pp 0.07
received antibiotic therapy that was initially established ac-
cording to the most likely etiological agent and later modified,
if necessary, when the in vitro susceptibility of the Staphylo-
coccus species became known. The overall mortality rate was
45% for case patients and 25% for control patients. The at-
tributable mortality rate was 25% (5 of 20 patients) for the
case patients and 18% (11 of 60 patients) for the control pa-
tients ( ), and the OR for death in patients with gly-PpNS
copeptide-resistant CoNS bacteremia was 1.48 (95% CI,
0.37–5.69). None of the patients had endocarditis or septic
shock. Five patients who died had teicoplanin-resistant S. ep-
idermidis bacteremia and were treated with vancomycin (3 case
patients) or aminoglycosides (2 case patients) for a mean du-
ration (SD) of days before death. The other 4 patients5 3
who died were treated with vancomycin, whereas 11 patients
who survived were treated with vancomycin (8 patients), im-
ipenem (2 patients), or aminoglycosides (1 patient). The mor-
tality rate among patients who presented with a severe APACHE
III score (mean, 51.8 vs. 27.6, for case and control patients,
respectively; ) and concomitant pneumonia (Pp 0.0007 Pp
) was significantly higher than that observed in patients0.008
without these variables. Treatment of teicoplanin-resistant
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Table 3. Logistic regression analysis of predictors for glyco-
peptide-resistant coagulase-negative staphylococci bacteremia.
Variables OR SE 95% CI P
Concomitant pneumonia 5.18 4.31 1.01–26.57 0.05
Previous glycopeptide use 19.86 20.59 2.60–151.60 0.004
Previous b-lactam use 19.64 20.18 2.62–147.21 0.004
No. of hospitalizations
during the year prior to
the study period 5.00 3.94 1.06–23.44 0.04
NOTE. SE, standard error.
Figure 2. Southern blot of chromosomal DNA showing a represen-
tative sample of the different patterns obtained by ribotyping of the
analyzed Staphylococcus epidermidis isolates. Lane A, strain 559 (inten-
sive care unit [ICU]); lane B, strain 528 (ICU); lane C, strain 520 (ICU);
lane D, strain 428 (cardiosurgery); lane E, strain 427 (medicine); lane F,
strain 346 (infectious diseases); lane G, strain 345 (ICU); lane H, strain
95 (medicine); lane I, strain 93 (cardiosurgery); lane L, strain 29 (ICU);
and lane M, l HindIII marker.
CoNS bacteremia with vancomycin was not associated with a
worse prognosis.
DISCUSSION
We determined the antimicrobial resistance of CoNS that cause
bacteremia in a large Italian university hospital and, as a novel
observation, we prospectively identified the risk factors that can
favor the emergence of glycopeptide-resistant infections. Al-
though studies published elsewhere have suggested some in
vitro factors that could influence the development of resistance
[26, 27], to our knowledge, none of the studies investigated
and identified the in vivo risk factors and the clinical signifi-
cance of “true” (according to CDC definitions) CoNS bacte-
remia caused by glycopeptide-resistant strains. Previous Eu-
ropean studies on CoNS glycopeptide resistance and the
European Glycopeptide Susceptibility Survey have indicated an
incidence rate (updated to 1995) ranging from 3% to 19%
[28–30].
Our prospective study (July 1998–June 1999) shows that 4%
of total isolates of CoNS are resistant to glycopeptides, with a
peak of incidence of 8% in the ICU. It is of note that all of
the strains were resistant to teicoplanin, and only 1 strain was
also resistant to vancomycin. This result suggests that the mech-
anisms of resistance for teicoplanin and vancomycin could be
different and that teicoplanin-resistant strains could also be
present in other countries where teicoplanin is not used; there-
fore, resistance against it is not tested. Although, in our study,
some staphylococcal strains were isolated in the same ward
(ICU), the high number of fingerprinting patterns ( )np 15
obtained among the 18 teicoplanin-resistant strains of S. epi-
dermidis supports the hypothesis that the spreading of a par-
ticular strain among the different wards has not occurred.
With regard to the second objective of the study—that is, to
assess risk factors—the results of our logistic regression analysis
clearly indicate that previous antibiotic therapy with glycopep-
tides and/or b-lactams, concomitant pneumonia, and multiple
hospital admissions during the year prior to the study period
were independent predictors for the development of glycopep-
tide-resistant CoNS bacteremia. It is important to emphasize
the relevance of multiple hospital admissions and concomitant
pneumonia, because they indirectly suggest the presence of a
patient’s severe underlying disease, despite a low statistical
weight for both of these variables. It is well known, in fact,
that such factors as severe clinical status, misuse or abuse of
antimicrobial agents, and invasive procedures all may contrib-
ute to a decrease in a patient’s resistance to exogenous bacteria
and to an increase in the risk of antibiotic-resistant infections
[31]. Moreover, this observation correlates well with the lack
of association between use of glycopeptides in an individual
ward and the glycopeptide resistance rate in the same ward,
with high DDDs for glycopeptides associated with a high re-
sistance rate in the ICU but not in other wards with identical
high DDDs. These data also confirm a recent observation [32]
that the susceptibility trend varies in the individual ward, de-
spite similar drug use characteristics, probably because other
cofactors, such as the ward “case mix,” may play an important
role in the development of antimicrobial resistance. Another
possible explanation is that, in our opinion, DDD, being the
average of the total drug use in an individual ward, might not
properly express the patient’s individual exposure to a single
drug, which is, on the contrary, witnessed by the results of
logistic regression analysis. In fact, our multivariate analysis
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Table 4. Fingerprinting patterns ob-
tained by ribotyping of 18 teicoplanin-
resistant strains of Staphylococcus
epidermidis.
Strain Ward Pattern
29 Intensive care unit A
93 Cardiosurgery A
95 Medicine A
345 Intensive care unit B
346 Infectious diseases C
427 Medicine D
428 Cardiosurgery E
520 Intensive care unit F
528 Intensive care unit G
559 Intensive care unit H
562 Intensive care unit I
564 Intensive care unit L
756 Intensive care unit M
788 Intensive care unit N




demonstrates a significant correlation between individual use
of a single drug and development of glycopeptide resistance.
The association between prior use of b-lactams and subsequent
infection caused by a strain that is resistant to glycopeptides has
been reported elsewhere by others [9] who demonstrated that
prior use of b-lactams may induce the expression of vancomycin
resistance in staphylococci. The mechanisms by which b-lactams
enhance the expression of this resistance are presently unknown.
Of interest, it has been demonstrated that vancomycin and tei-
coplanin resistance in S. aureus correlates with an increased pro-
duction of penicillin-binding protein 2 [33].
With regard to outcome, an aspect not previously studied,
the difference between mortality rates among case patients and
control patients, did not reach statistical significance in our
study, probably because of the relatively low number of case
patients. In addition, resistance to glycopeptides seems to be a
marker of severity of the underlying illness. In fact, patients
who died of glycopeptide-resistant bacteremia had concomitant
pneumonia and high APACHE III scores. However, it is inter-
esting to speculate that, if we eliminate the impact of glyco-
peptide resistance, the excess mortality rate attributable to an-
tibiotic resistance might be eventually reduced to a magnitude
of 38%.
In summary, we conclude that individual exposure to gly-
copeptides and b-lactams, in association with a history of mul-
tiple hospitalization and concomitant pneumonia, plays a piv-
otal role as risk factor for the development of glycopeptide
resistance. On the basis of our statistical analysis, we are also
confident to suggest that it is desirable, although not essential,
to implement the antibiotic restriction policy suggested by the
CDC [16] for the aforementioned high-risk patients, not only
to prevent the spread of CoNS glycopeptide-resistant bacte-
remia, but also to reduce the mortality rate, duration of hos-
pitalization, and cost of hospital care.
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